Abstract:Ruthenium(II) polypyridyl complexes have drawn growing attention due to their photophysical properties and anticancer activity. Herein we report four ruthenium(II) polypyridyl complexes [(N^N)2RuII(L)]2+ (1-4, L = 4-anilinoquinazoline derivatives, N^N = bidentate ligands with bis-nitrogen donors) as multi-functional anticancer agents. The epidermal growth factor receptor (EGFR) is overexpressed in a broad range of cancer cells and related to many kinds of malignance. EGFR inhibitors, such as gefitinib and erlotinib, have been approved as clinical anticancer drugs. The EGFR-inhibiting 4-anilinoquinazoline ligands greatly enhanced the in vitro anticancer activity of these ruthenium(II) polypyridyl complexes against a series of human cancer cell lines compared to [Ru(bpy)2(phen)], but interestingly, these complexes were actually not potent EGFR inhibitors. Further mechanism studies revealed that upon irradiation with visible light, complexes 3 and 4 generated a high level of singlet oxygen (1O2), and their in vitro anticancer activities against human non-small-cell lung (A549), cervical (HeLa) and squamous (A431) cancer cells were significantly improved. Specifically, complex 3 displayed potent phototoxicity upon irradiation with blue light, of which the photo-toxicity indexes (PIs) against HeLa and A431 cells were 11 and 8.3, respectively. These complexes exhibited strong fluorescence emission at ca. 600 nm upon excitation at about 450 nm. A subcellular distribution study by fluorescence microscopy imaging and secondary ion mass spectrometry imaging (ToF-SIMS) demonstrated that complex 3 mainly localized at the cytoplasm and complex 4 mainly localized in the nuclei of cells. Competitive binding with ctDNA showed that complex 4 was more favorable to bind to the DNA minor groove than complex 3. These differences support that complex 3 possibly exerts its anticancer activities majorly by photo-induced 1O2 generation and complex 4 by binding to DNA.

A Selenium-Containing Ruthenium Complex As a Cancer Radiosensitizer, Rational Design and the Important Role of ROS-mediated Signalling

Rational Design of Ruthenium Complexes Containing 2,6‐bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing P53 Activation

Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.

Selenium-containing Metallodrug Overcomes Cervical Cancer Radioresistance Through Physical-Chemical Dual Sensitization.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Biocompatible Ruthenium Polypyridyl Complexes As Efficient Radiosensitizers.

X-ray sensitive selenium-containing Ru complexes sensitize nasopharyngeal carcinoma cells for radio/chemotherapy

Selenium-containing metallodrug overcomes cervical cancer radioresistance by physical-chemical dual sensitization

Selenium-platinum coordination compounds as novel anticancer drugs: selectively killing cancer cells via a reactive oxygen species (ROS)-mediated apoptosis route.

Cancer-targeting Functionalization of Selenium-Containing Ruthenium Conjugate with Tumor Microenvironment-Responsive Property to Enhance Theranostic Effects.

Anticancer Activity of Novel Ruthenium Complex with 1,10-Phenanthrolineselenazole As Potent Telomeric G-Quadruplex Inhibitor

Ruthenium(II) Polypyridyl Complexes: Cellular Uptake, Cell Image and Apoptosis of HeLa Cancer Cells Induced by Double Targets

Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives Induce Cancer Cell Apoptosis by Triggering Dna Damage-Mediated P53 Phosphorylation

Ruthenium(II) salicylate complexes inducing ROS-mediated apoptosis by targeting thioredoxin reductase.

A Novel Ruthenium(ii)-Polypyridyl Complex Inhibits Cell Proliferation and Induces Cell Apoptosis by Impairing DNA Damage Repair.

Ruthenium–Porphyrin Complexes Induce Apoptosis by Inhibiting the Generation of Intracellular Reactive Oxygen Species in the Human Hepatoma Cell Line (Hepg2)

Rational Design of Cancer-Targeted Selenadiazole Derivative As Efficient Radiosensitizer for Precise Cancer Therapy

Ruthenium Polypyridyl Complexes That Induce Mitochondria-Mediated Apoptosis In Cancer Cells

Ruthenium(II) Polypyridyl Complexes with Visible Light-Enhanced Anticancer Activity and Multimodal Cell Imaging.

Sonoinduced Tumor Therapy and Metastasis Inhibition by a Ruthenium Complex with Dual Action: Superoxide Anion Sensitization and Ligand Fracture

Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage.